Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06419179 |
| Title | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE) |
| Acronym | GUIDANCE |
| Recruitment | Enrolling by invitation |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | University of Cologne |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DEU |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University Hospital Cologne | Cologne | North Rhine-Westphalia | 50937 | Germany | Details |